Innovating Works

SYREON

Desconocido
Thera4Care: THERANOSTICS ECOSYSTEM FOR PERSONALISED CARE Thera4Care represents a large unique consortium, gathering well-established European academic radiotheranostic centres, strong industry part...
2024-09-13 - 2029-09-30 | Financiado
DE-ESCALATE: INTERMITTENT ANDROGEN DEPRIVATION THERAPY IN THE ERA OF ANDROGEN RECEPTOR PATHWAY INHIBITORS; A PHAS... SYREON KUTATO INTEZET KORLATOLT FELELOSSEGU TARSASAG participó en un HORIZON EUROPE: HORIZON-MISS-2022-CANCER-01 Prostate Cancer is the most common cancer in European men. Despite dramatic improvements in early diagnostic and local treatment, one out of...
2023-04-21 - 2028-05-31 | Financiado
IMMUTOL: ADVANCED ANTIGEN-SPECIFIC DENDRITIC CELL-BASED THERAPY TO RE-ESTABLISH TOLERANCE IN IMMUNE-MEDIATED... SYREON KUTATO INTEZET KORLATOLT FELELOSSEGU TARSASAG participó en un HORIZON EUROPE: HORIZON-HLTH-2022-DISEASE-06-two-stage Autoimmune diseases are currently treated with immunosuppressive and supportive therapies, which dampen inflammation, but do not stop the ca...
2023-04-14 - 2027-04-30 | Financiado
REMEDI4ALL: BUILDING A SUSTAINABLE EUROPEAN INNOVATION PLATFORM TO ENHANCE THE REPURPOSING OF MEDICINES FOR ALL SYREON KUTATO INTEZET KORLATOLT FELELOSSEGU TARSASAG participó en un HORIZON EUROPE: HORIZON-HLTH-2021-DISEASE-04 REMEDI4ALL aims to establish Europe's leadership globally in the repurposing of medicines by creating a vibrant community of practice coveri...
2022-05-19 - 2027-08-31 | Financiado
EU-TOPIA-EAST: TOwards imProved screening for breast cervical and colorectal cancer in Eastern Europe Equitable... SYREON KUTATO INTEZET KORLATOLT FELELOSSEGU TARSASAG participó en un H2020: H2020-SC1-BHC-2018-2020 Colorectal, breast and cervical cancer cause 155,000 deaths each year in middle income countries (MIC) in Eastern Europe, while there is goo...
2021-02-04 - 2026-04-30 | Financiado
VITAL: Vaccines and Infectious Diseases in the Ageing PopuLation SYREON KUTATO INTEZET KORLATOLT FELELOSSEGU TARSASAG participó en un H2020: H2020-JTI-IMI2-2017-12-two-stage Today’s major challenge is to improve efficacy of vaccines to protect the growing ageing population against infectious diseases (ID). The VI...
2018-12-10 - 2024-12-31 | Financiado
HTx: Next Generation Health Technology Assessment to support patient centred societally oriented real t... SYREON KUTATO INTEZET KORLATOLT FELELOSSEGU TARSASAG participó en un H2020: H2020-SC1-BHC-2018-2020 HTx will create a framework for next generation Health Technology Assessment (HTA) that supports patient-centred, societally oriented, and r...
2018-12-03 - 2024-06-30 | Financiado
HEcoPerMed: Healthcare and pharma economic models in support of the International Consortium for Personalised M... SYREON KUTATO INTEZET KORLATOLT FELELOSSEGU TARSASAG participó en un H2020: H2020-SC1-BHC-2018-2020 HEcoPerMed responds to the demand for economic models that evaluate treatments made possible through innovations in personalised medicine an...
2018-11-07 - 2022-06-30 | Financiado
COMED: Pushing the boundaries of Cost and Outcome analysis of Medical Technologies SYREON KUTATO INTEZET KORLATOLT FELELOSSEGU TARSASAG participó en un H2020: H2020-SC1-2016-2017 The overarching objective of the COMED project is to push the boundaries of existing methods for cost and outcome analysis of healthcare tec...
2017-11-21 - 2021-06-30 | Financiado
EU-TOPIA: EU TOPIA TOWARDS IMPROVED SCREENING FOR BREAST CERVICAL AND COLORECTAL CANCER IN ALL OF EUROPE SYREON KUTATO INTEZET KORLATOLT FELELOSSEGU TARSASAG participó en un H2020: H2020-PHC-2014-2015 Breast, colorectal and cervical cancer cause 250,000 deaths each year, representing 20% of EU-cancer mortality. Although important progress...
2015-04-13 - 2020-08-31 | Financiado
SELFIE: Sustainable intEgrated care modeLs for multi morbidity delivery FInancing and performancE SYREON KUTATO INTEZET KORLATOLT FELELOSSEGU TARSASAG participó en un H2020: H2020-PHC-2014-2015 Over 50 million people in Europe have more than one chronic disease. This number will increase dramatically in the near future. This will in...
2015-03-27 - 2019-08-31 | Financiado
EQUIPT: European study on Quantifying Utility of Investment in Protection from Tobacco SYREON KUTATO INTEZET KORLATOLT FELELOSSEGU TARSASAG participó en un FP7: Tobacco smoking costs the EU an estimated 98 to 130 billion Euros each year – just above 1% of the EU Gross Domestic Product in 2000. A larg...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.